Search Results

In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma that appeared in the October issue of JNCCN ( JNCCN 2011;9:1146-1183), an error appears in the Lenalidomide as Maintenance Therapy After Autologous SCT

Background: This study evaluated risk factors predicting unplanned 30-day acute service utilization among adult inpatients subsequent to initial hospitalization for a new diagnosis of leukemia, lymphoma, or myeloma, with a focus on social

Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open-label phase I dose-escalation safety study of bortezomib in combination with pralatrexate in patients with

opposed to outpatient thromboprophylaxis, with the exception of IMid-based regimens in patients with myeloma, because it has not been shown to improve survival, because prophylaxis may be expensive and because of concerns regarding extrapolation to larger

/Refractory Multiple Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open-label, phase I, dose-escalation safety study of bortezomib in combination with pralatrexate in patients

A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma Principal Investigator: Michaela Liedtke, MD Condition: Multiple myeloma Institution: Stanford University This is an open

marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies . Hematol Oncol Clin North Am 2007 ; 21 : 1007 - 1034 , vii–viii . 5. Jones PA Baylin SB . The fundamental role

follicular lymphoma. Between these sessions, a second debate evaluated the appropriate length of initial treatment of multiple myeloma. The congress also included 3 interactive sessions featuring patient case studies and panel discussions. In the first